What is Biolytica?

Biolytica is a platform that enables rapid analyses of complex healthcare data by clinical and allied health care professionals.

The platform contains analytics that are relevant to biomedical research and clinical pratice and their application could save lives and money.

Biolytica offers more than just an analytical package: using high performance computing, the platform has the ability to hold large datasets in a secure environment. This allows effortless data sharing in a trusted environment and greatly reduces upload time.

It facilitates the establishment of common “language” and enables closer alignment of collaborative groups to better harness and improve their investigations.

When was Biolytica created?

What makes Biolytica stand out?

Biolytica offers a scalable solution for analysing large complex health datasets. Users can pseudo-anonymise data conforming to EU regulations. The security measures ensure that data and results are solely accessible by users with the necessary access requirements.

The Biolityca platform can be used for research purposes as well as in everyday clinical practice. The two user interfaces that facilitate this multipurpose use (a research-oriented user interface (R&D-UI) and a clinical decision support user interface (CDS-UI) can be customised to the needs of the user.

The Biolytica platform currently offers analytics for three disciplines, namely bioinformatics research (NGS and immunogenetics data, intensive care unit reseach and practice (monitoring data) and research in non-malignant chronic diseases such as diabetes (EHR data). The platform however is customisable, and able to support any other discipline in need of healthcare big data processing.

What do Biolytica users say?

The Biolytica platform currently enables researchers and practitioners in three healthcare domains to analyse their data. The Biolytica analytics support analysis of next generation sequencing and immunogenetics data, analysis of monitoring data from Intensive Care Units and analysis of electronic health record data from non-malignant chronic diseases.

This is what Biolytica users from various healthcare domains say about the platform

Chronic Lymphocytic Leukemia
Type 2 Diabetes
Intensive Care Unit
Richard Rosenquist image profile
Richard Rosenquist
Professor Uppsala University
Paolo Ghia image profile
Dr. Paolo Ghia
Associate professor of Internal Medicine Università Vita-Salute San Raffaele and Ospedale San Raffaele, Milano, Italy
John Chang image profile
John Chang
Director/Consultant Pediatrician Croydon Health Sevices – NHS Trust
John Rumbold image profile
John Rumbold
Senior Research Fellow School of Science & Technology Nottingham Trent University, UK
Katerina Vaporidi image profile
Katerina Vaporidi
Assistant Professor in Intensive Care Medicine University of Crete, School of Medicine, Greece
Andreas Agathangelidis image profile
Andreas Agathangelidis
Post-Doc Researcher Institute of Applied Bioscience (INAB), CERTH

How can you test it?

Ask for a demo

Do you want to experience the BIOLYTICA Platform?

Contact us for a demonstration!

A partner will take you through the Platform and show you its main functionalities. You will be able to experiment yourself with a fictional dataset!

Fill in the following form if you want a trial:

The information you are going to send will be stored and processed through email with the only purpose of answering to your contact request. The data you are going to submit will be used by other GLOBAZ SA departments. GLOBAZ SA will handle your personal information with the highest level of confidentiality and safety in accordance with the data protection regulations. You may withdraw your data use consent at any time. For this, you must contact our customer support service through the following email: info@biolytica.eu

The Biolytica Platform is a product of the AEGLE Project, an H2020 co-funded framework programme of the European Union under Grant Agreement no. 644906. The consortium of the project is combined of the following organisations:

Contact us

By continuing to use the Website after having been informed of the use of cookies, social media plugins and pixels, you acknowledge that you have read this Cookie Policy carefully and that you agree with it without reservation. You may, however, at all times change your cookie preferences through the cookie settings.